Combined with prognostic nutritional index and IgM for predicting the clinical outcomes of gastric cancer patients who received surgery

Objective Although the survival rate of patients who undergo surgery for gastric cancer has greatly improved, still many patients have a poor prognosis. This retrospective study aimed to investigate the predictive ability of the PNI-IgM score, a combined prognostic nutritional index (PNI), and immunoglobulin M (IgM), on the prognosis of patients undergoing surgery for gastric cancer. Methods 340 patients with gastric cancer who underwent surgery from January 2016 to December 2017 were selected. The PNI-IgM score ranged from 1 to 3: score of 1, low PNI (< 48.45) and low IgM (< 0.87); score of 2, low PNI and high IgM, or high PNI and low IgM; score of 3, high PNI and high IgM. We compared the differences in disease-free survival (DFS) and overall survival (OS) among the three groups, while univariate and multivariate analyses calculated prognostic factors for DFS and OS. In addition, the nomograms were constructed based on the results of multivariate analysis to estimate the 1-, 3- and 5-year survival probability. Results There were 67 cases in the PNI-IgM score 1 group, 160 cases in the PNI-IgM score 2 group, and 113 cases in the PNI-IgM score 3 group. The median survival times of DFS in the PNI-IgM score group 1, the PNI-IgM score group 2, and the PNI-IgM score group 3 were 62.20 months, not reached, and not reached, and 67.57 months vs. not reached vs. not reached in three groups for OS. Patients in the PNI-IgM score group 1 had a lower DFS than the PNI-IgM score group 2 (HR = 0.648, 95% CI: 0.418-1.006, P = 0.053) and the PNI-IgM score group 3 (HR = 0.337, 95% CI: 0.194-0.585, P < 0.001). In stratified analysis, PNI-IgM score 1 had a worse prognosis in the age < 60 years group and CA724 < 2.11 U/m group. Conclusion PNI-IgM score is a novel combination of nutritional and immunological markers that can be used as a sensitive biological marker for patients with gastric cancer who undergo surgery. The lower the PNI-IgM score, the worse the prognosis.

[1]  Haoran Sun,et al.  Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors , 2022, Frontiers in Nutrition.

[2]  Shulan Sun,et al.  Predictive value of NLR and PLR in response to preoperative chemotherapy and prognosis in locally advanced gastric cancer , 2022, Frontiers in Oncology.

[3]  Shuiping Huang,et al.  Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5‐positive diffuse large B‐cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group , 2022, Cancer.

[4]  Yasuhiro Chikaishi,et al.  Serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer , 2022, Thoracic cancer.

[5]  Yahui Liu,et al.  Prognostic Significance of PNI in Patients With Pancreatic Head Cancer Undergoing Laparoscopic Pancreaticoduodenectomy , 2022, Frontiers in Surgery.

[6]  K. Beckmann,et al.  Antibodies as biomarkers for cancer risk: a systematic review , 2022, Clinical and experimental immunology.

[7]  Haoran Sun,et al.  Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes , 2022, Frontiers in Pharmacology.

[8]  Wanqing Chen,et al.  Cancer statistics in China and United States, 2022: profiles, trends, and determinants , 2022, Chinese medical journal.

[9]  D. Carbone,et al.  Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. , 2022, Clinical lung cancer.

[10]  H. Kanemoto,et al.  Serum carnitine as a biomarker of sarcopenia and nutritional status in preoperative gastrointestinal cancer patients , 2021, Journal of cachexia, sarcopenia and muscle.

[11]  A. Gavin,et al.  International variation in oesophageal and gastric cancer survival 2012–2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study) , 2021, Gut.

[12]  L. Xu,et al.  124例成人噬血细胞综合征临床预后分析：一项淮海淋巴瘤协作组多中心回顾性研究 , 2021, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[13]  Kailin Xu,et al.  Prognostic values of geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI) in elderly patients with Diffuse Large B-Cell Lymphoma , 2021, Journal of Cancer.

[14]  Shuiping Huang,et al.  The Value of Prognostic Nutritional Index (PNI) on Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: A Multicenter Retrospective Study of HHLWG Based on Propensity Score Matched Analysis , 2021, Journal of inflammation research.

[15]  C. Kou,et al.  Prognostic role of the prognostic nutritional index (PNI) in patients with head and neck neoplasms undergoing radiotherapy: A meta-analysis , 2021, PloS one.

[16]  F. Tan,et al.  Association between pre‐diagnostic serum albumin and cancer risk: Results from a prospective population‐based study , 2021, Cancer medicine.

[17]  X. Kong,et al.  Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator , 2021, Frontiers in Cell and Developmental Biology.

[18]  P. Ravasco,et al.  ESPEN practical guideline: Clinical Nutrition in cancer. , 2021, Clinical nutrition.

[19]  Myung-Gyu Choi,et al.  Association between absolute lymphocyte count and overall mortality in patients with surgically resected gastric cancer , 2021, The Korean journal of internal medicine.

[20]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[21]  G. Kijanka,et al.  IgM and IgA augmented autoantibody signatures improve early‐stage detection of colorectal cancer prior to nodal and distant spread , 2021, Clinical & translational immunology.

[22]  T. S. S. Pereira,et al.  Malnutrition and nutrition impact symptoms (NIS) in surgical patients with cancer , 2020, PloS one.

[23]  A. Shen,et al.  Combining the Fibrinogen-to-Pre-Albumin Ratio and Prognostic Nutritional Index (FPR-PNI) Predicts the Survival in Elderly Gastric Cancer Patients After Gastrectomy , 2020, OncoTargets and therapy.

[24]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[25]  Lan Xu,et al.  Evaluation of IgG, IgM, CD4+ and CD8+ T cells during neoadjuvant chemotherapy with Tezio and Apatinib in gastric cancer patients. , 2020, Cellular and molecular biology.

[26]  K. Shiu,et al.  Challenges in the treatment of gastric cancer in the older patient. , 2020, Cancer treatment reviews.

[27]  S. Natsugoe,et al.  Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer , 2019, BMC cancer.

[28]  E. Kay,et al.  Measurement of the IgM and IgG Autoantibody Immune Responses in Human Serum has High Predictive Value for the Presence of Colorectal Cancer , 2019, Clinical colorectal cancer.

[29]  Vítor Devezas,et al.  The impact of the prognostic nutritional index (PNI) in gastric cancer , 2019, Langenbeck's Archives of Surgery.

[30]  N. Deutz,et al.  Specialized High‐Protein Oral Nutrition Supplement Improves Home Nutrient Intake of Malnourished Older Adults Without Decreasing Usual Food Intake , 2018, JPEN. Journal of parenteral and enteral nutrition.

[31]  R. Torres,et al.  Immune Surveillance by Natural IgM Is Required for Early Neoantigen Recognition and Initiation of Adaptive Immunity , 2018, American journal of respiratory cell and molecular biology.

[32]  Chang-ming Huang,et al.  CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial , 2018, Gastric Cancer.

[33]  D. Waitzberg,et al.  Nutritional Therapy in Gastrointestinal Cancers. , 2017, Gastroenterology clinics of North America.

[34]  W. Guan,et al.  Postoperative decrease of serum albumin predicts short-term complications in patients undergoing gastric cancer resection , 2017, World journal of gastroenterology.

[35]  R. Knols,et al.  Effects of nutrition and physical exercise intervention in palliative cancer patients: A randomized controlled trial. , 2017, Clinical nutrition.

[36]  M. Kontogianni,et al.  Detailed Dietary Assessment in Patients with Inoperable Tumors: Potential Deficits for Nutrition Care Plans , 2016, Nutrition and cancer.

[37]  T. Yoshikawa,et al.  Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. , 2016, European journal of cancer.

[38]  T. Nagykálnai,et al.  [Cachexia in cancer patients]. , 2016, Magyar onkologia.

[39]  G. Freeman,et al.  Combination cancer immunotherapy and new immunomodulatory targets , 2015, Nature Reviews Drug Discovery.

[40]  P. Ostoa-Saloma,et al.  Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review) , 2015, Oncology reports.

[41]  S. Choi,et al.  Absolute monocyte and lymphocyte count prognostic score for patients with gastric cancer. , 2015, World journal of gastroenterology.

[42]  S. Clarke,et al.  Cancer-related inflammation and treatment effectiveness. , 2014, The Lancet. Oncology.

[43]  C. Leemans,et al.  Effect of nutritional interventions on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo)radiotherapy: a systematic review. , 2013, Clinical nutrition.

[44]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[45]  S. Kaveri,et al.  Natural IgM in Immune Equilibrium and Harnessing Their Therapeutic Potential , 2012, The Journal of Immunology.

[46]  Y. Bang,et al.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.

[47]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  K. Fearon.  Cancer cachexia: developing multimodal therapy for a multidimensional problem. , 2008, European journal of cancer.

[49]  F. Schmidt.  Meta-Analysis , 2008 .

[50]  M. Tattersall,et al.  Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review , 2006, Supportive Care in Cancer.

[51]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[52]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.